TL
Therapeutic Areas
HilleVax Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HIL-214 | Prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection | Phase 2b/3 |
Leadership Team at HilleVax
RH
Rob Hershberg
Executive Chairman of the Board
AB
A. Bruce Montgomery
Chief Executive Officer and Director
DS
David Socks
Chief Financial Officer and Director
AK
Aditya Kohli
Chief Operating Officer
PB
Paul Bavier
General Counsel
J(
James (Jim) F. Young
Chief Scientific Officer
SG
Sheila Gujrathi
Former Chief Executive Officer
EO
Elaine O'Hara
Director
JP
John P. Richard
Director
MK
Michael Kamarck
Director